At OrganOx our mission is to save lives by making every donated organ count

While transplantation waiting lists continue to impact patient outcomes, over a third of deceased donors in the UK do not result in a transplanted liver.1

At OrganOx we believe that there is a better way; functional assessment of donor organs prior to transplant, resulting in fewer discarded organs and increased transplantation rates.2,3 We are passionate about transforming transplantation and achieving our mission of saving lives by making every donor organ count.

"OrganOx is aiming to dramatically improve two of the key issues which are synonymous with liver transplantation, namely shortage of transplantable donor organs and urgency.

The OrganOx metra® allows our customers to "test drive" a donor liver thereby evaluating its function prior to transplant. Armed with this new level of information we are typically seeing utilisation levels increase by at least 25%. Furthermore, we are able to provide our customers with a significantly extended preservation period between the point of donation and the transplant, in fact we have some customers who no longer perform night time transplants, thanks to the OrganOx metra. This can improve the work-life balance for the surgeons, anaesthetists and the whole transplant team.

More transplantable donor organs and less urgency means more transplants, delivering on our mission to make every donor organ count.”

Craig Marshall, Chief Executive Officer

Our Values

Innovation, evidence and integrity

Teamwork and respect

Passionate about transplantation

Current opportunities to join our team

Located in our offices at the Oxford Science Park, Oxford, UK, and in field-based positions throughout the world, OrganOx seeks to recruit and retain the best people from a broad range of backgrounds.

See opportunities



References: 1. NHS Blood and Transplant. Organ Donation and Transplantation Activity Report 2017/18. 2. Nasralla D et al. Nature 2018; 557(7703):50–56. 3. Mergental H et al. Hepatology 2018; 68(1):(Suppl).

UK/US MD-040-3-1 - September 2022